ARTICLES BY MARTIN LUSH
-
![iStock-472096302]( "Rebels Vs. Clones: Constructive Dissent In The Pharma Industry")
Rebels Vs. Clones: Constructive Dissent In The Pharma Industry12/20/2019The pharma industry is in the middle of an identity crisis, but not in the way you may think. Rather than a period of uncertainty and confusion typically brought on by a change in role or expectations, this crisis is far more insidious. It’s brought on by a mind-set in which industry leaders believe they know exactly what the industry should be doing.
-
![15 Bold Predictions About Healthcare’s Future — And What Bio/Pharma Must Do To Prosper In It]( "15 Bold Predictions About Healthcare’s Future — And What Bio/Pharma Must Do To Prosper In It")
15 Bold Predictions About Healthcare’s Future — And What Bio/Pharma Must Do To Prosper In It3/30/2018Ever participated on one of those benchmarking exercises? You know what I mean: a (usually) fresh-faced consultant asks lots of questions and fills in a spreadsheet comparing what you do with your competitors. Well, beware.
-
![center for drug evalutaiton and research inspection]( "Responding To Regulatory Inspection Observations: Do’s And Don’ts")
Responding To Regulatory Inspection Observations: Do’s And Don’ts6/26/2017Although good auditors base conclusions on facts, emotions will play an important role in how they perceive your company, your leadership, and your quality culture. This is not a precise process, and cultural differences can often sabotage good intent.
Martin Lush
Martin Lush is vice president of health sciences at NSF International, an independent organization whose mission is to improve and protect human health by supporting the development of and adherence to drug and med device manufacturing standards. Lush’s group provides training, consultation, testing, and project-specific support of pharma and medical device companies to help them stay compliant and incite them to think differently to solve chronic problems. You can contact him at martinlush@nsf.org.